Summit Therapeutics Shares Drop Despite Positive Lung Cancer Treatment Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Clinical Trial Results: The HARMONi-6 study indicated that ivonescimab combined with chemotherapy reduced the risk of death by 34% compared to BeOne Medicines' Tevimbra plus chemotherapy, with a median overall survival of 27.89 months for ivonescimab versus 23.69 months for tislelizumab at a median follow-up of 21.36 months.
- Market Reaction: Despite the positive clinical data release, Summit Therapeutics' stock fell approximately 10% on Monday, reflecting cautious market sentiment likely due to concerns over the applicability of the trial results.
- Study Limitations: Conducted in China with a homogeneous population, the study's findings raise concerns about their real-world applicability, which may have undermined investor confidence in the stock.
- Analyst Rating Changes: Following the release of Merck's data, H.C. Wainwright downgraded Summit Therapeutics, further exacerbating market concerns regarding the company's future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SMMT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SMMT
Wall Street analysts forecast SMMT stock price to rise
12 Analyst Rating
8 Buy
3 Hold
1 Sell
Moderate Buy
Current: 17.540
Low
18.00
Averages
42.49
High
131.90
Current: 17.540
Low
18.00
Averages
42.49
High
131.90
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Summit Therapeutics Shares Drop Despite Positive Lung Cancer Treatment Data
- Clinical Trial Results: The HARMONi-6 study indicated that ivonescimab combined with chemotherapy reduced the risk of death by 34% compared to BeOne Medicines' Tevimbra plus chemotherapy, with a median overall survival of 27.89 months for ivonescimab versus 23.69 months for tislelizumab at a median follow-up of 21.36 months.
- Market Reaction: Despite the positive clinical data release, Summit Therapeutics' stock fell approximately 10% on Monday, reflecting cautious market sentiment likely due to concerns over the applicability of the trial results.
- Study Limitations: Conducted in China with a homogeneous population, the study's findings raise concerns about their real-world applicability, which may have undermined investor confidence in the stock.
- Analyst Rating Changes: Following the release of Merck's data, H.C. Wainwright downgraded Summit Therapeutics, further exacerbating market concerns regarding the company's future prospects.
See More
ManpowerGroup and Zoom Communications See High Options Trading Volume
- ManpowerGroup Options Activity: ManpowerGroup Inc (Ticker: MAN) saw options trading volume of 7,788 contracts today, equating to approximately 778,800 shares, which represents about 88% of its average daily trading volume of 885,240 shares over the past month, indicating heightened market interest in its future performance.
- High Demand Options: Among MAN's options, the $40 strike call option expiring on June 18, 2026, was particularly active with 6,810 contracts traded, representing approximately 681,000 shares, suggesting bullish sentiment among investors at this price level.
- Zoom Options Activity: Concurrently, Zoom Communications Inc (Ticker: ZM) experienced options trading volume of 46,765 contracts today, translating to around 4.7 million shares, which is about 85.4% of its average daily trading volume of 5.5 million shares over the past month, reflecting strong market activity.
- Zoom High Demand Options: Within ZM's options, the $115 strike call option expiring on July 17, 2026, saw a notable trading volume of 3,123 contracts, representing approximately 312,300 shares, indicating optimistic expectations from investors regarding its future growth.
See More
MGM Resorts Shares Surge 16% on Acquisition Proposal
- Acquisition Proposal Surge: MGM Resorts International shares surged 16% following an acquisition offer from Barry Diller's People Inc. at $48.30 per share in cash, indicating strong market optimism that could alter the company's control structure.
- Zoom Platform Rebound: Zoom Communications saw its shares jump over 11% after Anthropic, an early investor, confidentially filed for an IPO with regulators, suggesting positive market expectations for investment returns and potentially enhancing Zoom's market position.
- Veeva Systems Strong Performance: Veeva Systems shares rose nearly 9% ahead of its first-quarter earnings report on Wednesday, with FactSet consensus expecting earnings of $2.14 per share and revenue of $857.7 million, both within the company's prior guidance range, indicating business stability.
- Humana Guidance Reaffirmation: Humana's shares increased by 8% after reaffirming its full-year adjusted earnings guidance of at least $9 per share, surpassing the FactSet consensus of $8.93, reflecting the company's strong performance and growth potential in the health insurance market.
See More
Nvidia and Microsoft Collaborate on New Processor Launch
- Nvidia and Microsoft Collaboration: Nvidia and Microsoft unveiled a new personal computer processor, leading to a 2% rise in Nvidia's stock and nearly 4% increase in Microsoft's premarket trading, indicating strong market enthusiasm for the new technology.
- Related Companies' Stock Movements: Dell and HP saw their stocks rise by 1.5% and over 3.5%, respectively, as they are set to manufacture computers featuring the new chip, while Arm, leveraging Nvidia's technology, surged 14.5%, reflecting robust demand for the new product.
- Taylor Morrison's Stock Surge: Shares of Taylor Morrison jumped nearly 23% after Berkshire Hathaway agreed to acquire the company for $6.8 billion, showcasing market recognition of high-quality homebuilders.
- IBM's Significant Stock Increase: International Business Machines saw a 13% stock increase after Barclays initiated coverage with an overweight rating, with analysts highlighting quantum computing as the next major computing paradigm, making IBM's strategy in this area particularly compelling.
See More
Ivonescimab Data Enhances Market Prospects Against Keytruda
- Survival Extension: The Phase 3 Harmoni-6 study presented at ASCO demonstrated that Ivonescimab combined with chemotherapy extended median overall survival from 23.7 months to 27.9 months, with nearly 65% of patients alive after two years, significantly enhancing its market competitiveness.
- Intensifying Industry Competition: The success of Ivonescimab has heightened pressure on major pharmaceutical players like Pfizer (PFE), Bristol Myers Squibb (BMY), and Merck (MRK), all of whom are advancing rival therapies, particularly in light of the impending patent cliff.
- FDA Review Progress: Summit Therapeutics has submitted an FDA application for Ivonescimab plus chemotherapy in EGFR-mutated lung cancer, with a regulatory decision expected by November 14, positioning the company advantageously in the competitive landscape.
- Investor Sentiment Rebound: Retail investor sentiment for SMMT surged to an all-time high of 97/100 on Stocktwits, with message volume increasing by over 9,200%, reflecting strong market confidence in the future potential of Ivonescimab.
See More
Chinese Biotech's Growing Impact on U.S. Stocks
- Emerging Risks from Chinese Innovation: Jefferies estimates that by 2025, about one-third of U.S. biotech licensing spending will be directed towards drugs developed in China, highlighting the rapid rise of Chinese biotech and posing potential threats to investment safety in U.S. firms.
- Clinical Trial Data Discrepancies: Summit Therapeutics' ivonescimab showed only a 33% reduction in progression-free survival for Western patients compared to 45% for Chinese patients in global phase 3 trials, raising concerns about FDA approval and increasing uncertainty for investors.
- Vulnerability of Big Pharma: While Merck has secured a $175 million deal with Kelun-Biotech, the risks associated with reliance on Chinese innovation remain, as they may face similar approval challenges as Summit, indicating potential fragility across the industry.
- Caution for Investors: Investors should scrutinize the source of a company's value before purchasing biotech stocks, as firms that develop their own drugs deserve higher valuations, while those relying on licensed products face additional risks that could lead to undervaluation.
See More
Summit Therapeutics Shares Drop Despite Positive Lung Cancer Treatment Data
- Clinical Trial Results: The HARMONi-6 study indicated that ivonescimab combined with chemotherapy reduced the risk of death by 34% compared to BeOne Medicines' Tevimbra plus chemotherapy, with a median overall survival of 27.89 months for ivonescimab versus 23.69 months for tislelizumab at a median follow-up of 21.36 months.
- Market Reaction: Despite the positive clinical data release, Summit Therapeutics' stock fell approximately 10% on Monday, reflecting cautious market sentiment likely due to concerns over the applicability of the trial results.
- Study Limitations: Conducted in China with a homogeneous population, the study's findings raise concerns about their real-world applicability, which may have undermined investor confidence in the stock.
- Analyst Rating Changes: Following the release of Merck's data, H.C. Wainwright downgraded Summit Therapeutics, further exacerbating market concerns regarding the company's future prospects.
See More
ManpowerGroup and Zoom Communications See High Options Trading Volume
- ManpowerGroup Options Activity: ManpowerGroup Inc (Ticker: MAN) saw options trading volume of 7,788 contracts today, equating to approximately 778,800 shares, which represents about 88% of its average daily trading volume of 885,240 shares over the past month, indicating heightened market interest in its future performance.
- High Demand Options: Among MAN's options, the $40 strike call option expiring on June 18, 2026, was particularly active with 6,810 contracts traded, representing approximately 681,000 shares, suggesting bullish sentiment among investors at this price level.
- Zoom Options Activity: Concurrently, Zoom Communications Inc (Ticker: ZM) experienced options trading volume of 46,765 contracts today, translating to around 4.7 million shares, which is about 85.4% of its average daily trading volume of 5.5 million shares over the past month, reflecting strong market activity.
- Zoom High Demand Options: Within ZM's options, the $115 strike call option expiring on July 17, 2026, saw a notable trading volume of 3,123 contracts, representing approximately 312,300 shares, indicating optimistic expectations from investors regarding its future growth.
See More
MGM Resorts Shares Surge 16% on Acquisition Proposal
- Acquisition Proposal Surge: MGM Resorts International shares surged 16% following an acquisition offer from Barry Diller's People Inc. at $48.30 per share in cash, indicating strong market optimism that could alter the company's control structure.
- Zoom Platform Rebound: Zoom Communications saw its shares jump over 11% after Anthropic, an early investor, confidentially filed for an IPO with regulators, suggesting positive market expectations for investment returns and potentially enhancing Zoom's market position.
- Veeva Systems Strong Performance: Veeva Systems shares rose nearly 9% ahead of its first-quarter earnings report on Wednesday, with FactSet consensus expecting earnings of $2.14 per share and revenue of $857.7 million, both within the company's prior guidance range, indicating business stability.
- Humana Guidance Reaffirmation: Humana's shares increased by 8% after reaffirming its full-year adjusted earnings guidance of at least $9 per share, surpassing the FactSet consensus of $8.93, reflecting the company's strong performance and growth potential in the health insurance market.
See More
Nvidia and Microsoft Collaborate on New Processor Launch
- Nvidia and Microsoft Collaboration: Nvidia and Microsoft unveiled a new personal computer processor, leading to a 2% rise in Nvidia's stock and nearly 4% increase in Microsoft's premarket trading, indicating strong market enthusiasm for the new technology.
- Related Companies' Stock Movements: Dell and HP saw their stocks rise by 1.5% and over 3.5%, respectively, as they are set to manufacture computers featuring the new chip, while Arm, leveraging Nvidia's technology, surged 14.5%, reflecting robust demand for the new product.
- Taylor Morrison's Stock Surge: Shares of Taylor Morrison jumped nearly 23% after Berkshire Hathaway agreed to acquire the company for $6.8 billion, showcasing market recognition of high-quality homebuilders.
- IBM's Significant Stock Increase: International Business Machines saw a 13% stock increase after Barclays initiated coverage with an overweight rating, with analysts highlighting quantum computing as the next major computing paradigm, making IBM's strategy in this area particularly compelling.
See More
Ivonescimab Data Enhances Market Prospects Against Keytruda
- Survival Extension: The Phase 3 Harmoni-6 study presented at ASCO demonstrated that Ivonescimab combined with chemotherapy extended median overall survival from 23.7 months to 27.9 months, with nearly 65% of patients alive after two years, significantly enhancing its market competitiveness.
- Intensifying Industry Competition: The success of Ivonescimab has heightened pressure on major pharmaceutical players like Pfizer (PFE), Bristol Myers Squibb (BMY), and Merck (MRK), all of whom are advancing rival therapies, particularly in light of the impending patent cliff.
- FDA Review Progress: Summit Therapeutics has submitted an FDA application for Ivonescimab plus chemotherapy in EGFR-mutated lung cancer, with a regulatory decision expected by November 14, positioning the company advantageously in the competitive landscape.
- Investor Sentiment Rebound: Retail investor sentiment for SMMT surged to an all-time high of 97/100 on Stocktwits, with message volume increasing by over 9,200%, reflecting strong market confidence in the future potential of Ivonescimab.
See More
Chinese Biotech's Growing Impact on U.S. Stocks
- Emerging Risks from Chinese Innovation: Jefferies estimates that by 2025, about one-third of U.S. biotech licensing spending will be directed towards drugs developed in China, highlighting the rapid rise of Chinese biotech and posing potential threats to investment safety in U.S. firms.
- Clinical Trial Data Discrepancies: Summit Therapeutics' ivonescimab showed only a 33% reduction in progression-free survival for Western patients compared to 45% for Chinese patients in global phase 3 trials, raising concerns about FDA approval and increasing uncertainty for investors.
- Vulnerability of Big Pharma: While Merck has secured a $175 million deal with Kelun-Biotech, the risks associated with reliance on Chinese innovation remain, as they may face similar approval challenges as Summit, indicating potential fragility across the industry.
- Caution for Investors: Investors should scrutinize the source of a company's value before purchasing biotech stocks, as firms that develop their own drugs deserve higher valuations, while those relying on licensed products face additional risks that could lead to undervaluation.
See More
